2017 VENTURE MADNESS COMPETITION – VOTE FOR THE PEOPLE’S CHOICE AWARD by 5:00 PM, on January 24thContinue reading
Author Archive: AZBio
Applications are Open for the Spring 2017 Arizona Innovation Challenge
Submission Window Open through February 17th!!Continue reading
SenesTech Rings the Closing Bell at Nasdaq.
SenesTech, Inc. (Nasdaq: SNES), a developer of novel proprietary technologies for managing animal pest populations through fertility control, visited the Nasdaq MarketSite in Times Square to ring the closing bell on Friday, January 20, 2017.Continue reading
It’s Time to Apply for MedTech Innovator
Applications for 2017 Are Now OpenContinue reading
Castle Biosciences’ New Laboratory Receives Accreditation from College of American Pathologists
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to its new state-of-the-art laboratory facility in Phoenix, AZ based on results of a recent onsite inspection as part of the CAP’s Accreditation Programs.
TGen identifies compound that could improve drug development against deadly brain cancer
ATA prevents glioblastoma cells from spreading, and leave them vulnerable to chemotherapy and radiation
Capstone Therapeutics Announces Profound, Rapid LDL Cholesterol Reduction in AEM-28-14 Primate Study
Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s drug development joint venture (“JV”) announced today that the JV’s lead commercial drug candidate, AEM-28-14, showed substantial and statistically-significant LDL cholesterol (LDLc) reductions in a hypercholesterolemic primate study at Wake Forest University. Following a single IV administration of escalating doses up to 5mg/kg, LDLc exhibited a mean reduction of 64% from baseline at 24 hours, 46% from baseline at 3 days and 16% from baseline at 7 days, despite the study animals remaining on a high fat/cholesterol diet through the full study.
Mayo Clinic first in U.S. to offer lymphoma genomic diagnostic test for patients
PHOENIX — Mayo Clinic has created a genetic test to help guide diagnosis and treatment of patients with diffuse large B-cell lymphoma, the most common type of non-Hodgkin’s lymphoma. The Lymph2Cx test helps determine where the lymphoma started, assigning “cell-of-origin” groups using a 20-gene expression-based assay. It is the first test to go into the Mayo practice from the new Mayo Clinic Molecular Diagnostic Arizona Laboratory. The lab enables Mayo physicians and researchers to access new and existing tests rapidly to improve patient care.Continue reading
Barrow identifies new genes responsible for ALS using IBM Watson Health
Findings pave way for potential new treatments to combat deadly disease. Continue reading
Dr. Leigh Neumayer named Interim Senior Vice president for Health Sciences
Leigh Neumayer, MD, MS, who heads the department of surgery at UA College of Medicine-Tucson, will be interim senior vice president for health sciences effective Jan. 1, 2017. UA Heath Sciences includes UA’s medical schools in Phoenix and Tucson and the colleges of nursing, pharmacy and public health.The total UA Heath Sciences budget is $595 million per year.Continue reading